NASDAQ:SOPH SOPHiA GENETICS (SOPH) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free SOPH Stock Alerts $4.93 -0.33 (-6.27%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.93▼$5.2150-Day Range$4.21▼$5.6252-Week Range$2.13▼$7.37Volume21,152 shsAverage Volume51,896 shsMarket Capitalization$321.58 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get SOPHiA GENETICS alerts: Email Address SOPHiA GENETICS MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside62.3% Upside$8.00 Price TargetShort InterestHealthy0.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.06) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 starsMedical Sector468th out of 938 stocksBiological Products, Except Diagnostic Industry75th out of 148 stocks 3.5 Analyst's Opinion Consensus RatingSOPHiA GENETICS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, SOPHiA GENETICS has a forecasted upside of 62.3% from its current price of $4.93.Amount of Analyst CoverageSOPHiA GENETICS has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.09% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently decreased by 28.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SOPH. Previous Next 2.5 News and Social Media Coverage News SentimentSOPHiA GENETICS has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for SOPH on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by InstitutionsOnly 31.59% of the stock of SOPHiA GENETICS is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($1.06) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SOPHiA GENETICS is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SOPHiA GENETICS is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSOPHiA GENETICS has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About SOPHiA GENETICS Stock (NASDAQ:SOPH)SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.Read More SOPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SOPH Stock News HeadlinesMarch 28, 2024 | msn.comAmericas dengue outbreak is the ‘worst to date’March 28, 2024 | msn.comA promising discovery in a rare neurodegenerative diseaseMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 28, 2024 | msn.comDiscovering the Hidden Science of Everyday WondersMarch 21, 2024 | msn.comUSask and Sophia Genetics partner to improve ovarian cancer trialMarch 15, 2024 | finance.yahoo.comSOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear CollaborationMarch 14, 2024 | msn.comThe Worms of Chernobyl Have Apparently Conquered RadiationMarch 9, 2024 | finance.yahoo.comSOPHiA GENETICS SA (NASDAQ:SOPH) Just Released Its Yearly Results And Analysts Are Updating Their EstimatesMarch 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 7, 2024 | seekingalpha.comSOPHiA GENETICS SA (SOPH) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | globenewswire.comSOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare ConferenceMarch 6, 2024 | marketwatch.comSophia Genetics Shares Sink After Weak 4Q, GuidanceMarch 6, 2024 | msn.comWhy SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SOPHiA GENETICS (SOPH), Green Thumb Industries (OtherGTBIF) and Marinus (MRNS)March 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for SOPHiA GENETICS Amid Growth and Market Expansion PotentialMarch 6, 2024 | finance.yahoo.comQ4 2023 Sophia Genetics SA Earnings CallMarch 6, 2024 | finance.yahoo.comSOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | finance.yahoo.comSOPHiA GENETICS Full Year 2023 Earnings: EPS Misses ExpectationsMarch 5, 2024 | msn.comSOPHiA Genetics misses top-line and bottom-line estimates; initiates FY24 outlookMarch 5, 2024 | globenewswire.comSOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 ResultsMarch 4, 2024 | benzinga.comPreview: Sophia Genetics's EarningsFebruary 25, 2024 | msn.comAll the red-carpet looks from the 2024 SAG AwardsFebruary 23, 2024 | msn.comPeople Who Follow Plant-Based Diet Are Less Prone To Obstructive Sleep Apnea: StudyFebruary 22, 2024 | finance.yahoo.comSOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care ConferenceFebruary 22, 2024 | globenewswire.comSOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care ConferenceFebruary 22, 2024 | theguardian.comSolar storms, ice cores and nuns’ teeth: the new science of historyFebruary 21, 2024 | msn.comHealthy plant-based diets linked to lower risk of obstructive sleep apneaSee More Headlines Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SOPH CUSIPN/A CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees430Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+62.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,980,000.00 Net Margins-126.63% Pretax Margin-125.85% Return on Equity-47.40% Return on Assets-36.43% Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio3.97 Sales & Book Value Annual Sales$62.37 million Price / Sales5.16 Cash FlowN/A Price / Cash FlowN/A Book Value$3.16 per share Price / Book1.56Miscellaneous Outstanding Shares65,230,000Free Float62,048,000Market Cap$321.58 million OptionableNot Optionable Beta1.18 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Jurgi Camblong M.B.A. (Age 45)Ph.D., Co-Founder, CEO & Director Comp: $1.1MMr. Ross Jordan Muken B.Sc. (Age 43)Executive VP, CFO & COO Mr. Abhimanyu VermaSenior VP & CTODr. Zhenyu Xu Ph.D. (Age 41)Executive VP & Chief Scientific Officer Katherine BailonVice President of Investor RelationsMr. Daan van Well L.L.M. (Age 49)M.B.A., Executive VP, Chief Legal & Compliance Officer Ms. Manuela Da Silva Valente B.A. (Age 53)Senior VP & Chief People Officer Mr. Kevin PuylaertVP & MD of EMEADr. Philippe Menu M.B.A. (Age 42)M.D., Ph.D., Executive VP, Chief Medical Officer & Chief Product Officer Mr. Peter CasasantoSenior VP & Chief BioPharma OfficerMore ExecutivesKey CompetitorsMonte Rosa TherapeuticsNASDAQ:GLUEVentyx BiosciencesNASDAQ:VTYXFennec PharmaceuticalsNASDAQ:FENCAdverum BiotechnologiesNASDAQ:ADVMAura BiosciencesNASDAQ:AURAView All CompetitorsInstitutional OwnershipParkman Healthcare Partners LLCBought 199,997 shares on 2/15/2024Ownership: 0.316%Essex Investment Management Co. LLCBought 123,901 shares on 2/8/2024Ownership: 0.000%Principal Financial Group Inc.Bought 24,837 shares on 2/7/2024Ownership: 0.000%Federated Hermes Inc.Sold 40,000 shares on 1/31/2024Ownership: 0.000%Zurcher Kantonalbank Zurich Cantonalbank Bought 6,552 shares on 1/30/2024Ownership: 0.000%View All Institutional Transactions SOPH Stock Analysis - Frequently Asked Questions Should I buy or sell SOPHiA GENETICS stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SOPH shares. View SOPH analyst ratings or view top-rated stocks. What is SOPHiA GENETICS's stock price target for 2024? 2 brokers have issued 1-year target prices for SOPHiA GENETICS's shares. Their SOPH share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 62.3% from the stock's current price. View analysts price targets for SOPH or view top-rated stocks among Wall Street analysts. How have SOPH shares performed in 2024? SOPHiA GENETICS's stock was trading at $4.71 on January 1st, 2024. Since then, SOPH shares have increased by 4.7% and is now trading at $4.93. View the best growth stocks for 2024 here. Are investors shorting SOPHiA GENETICS? SOPHiA GENETICS saw a drop in short interest in March. As of March 15th, there was short interest totaling 43,000 shares, a drop of 28.6% from the February 29th total of 60,200 shares. Based on an average daily trading volume, of 48,100 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.1% of the company's stock are short sold. View SOPHiA GENETICS's Short Interest. When is SOPHiA GENETICS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SOPH earnings forecast. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) issued its earnings results on Tuesday, March, 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.12. The firm earned $17.05 million during the quarter, compared to the consensus estimate of $16.78 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 47.40% and a negative net margin of 126.63%. During the same quarter in the prior year, the firm earned ($0.22) EPS. What guidance has SOPHiA GENETICS issued on next quarter's earnings? SOPHiA GENETICS updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $78.0 million-$81.0 million, compared to the consensus revenue estimate of $82.1 million. When did SOPHiA GENETICS IPO? SOPHiA GENETICS (SOPH) raised $234 million in an IPO on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share. Who are SOPHiA GENETICS's major shareholders? SOPHiA GENETICS's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (0.00%), Parkman Healthcare Partners LLC (0.32%), Essex Investment Management Co. LLC (0.00%), Federated Hermes Inc. (0.00%), Legato Capital Management LLC (0.00%) and Zurcher Kantonalbank Zurich Cantonalbank (0.00%). How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SOPH) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.